ELARA: Bulky disease
Outcomes with tisa-cel in POD24 patients
Efficacy
PFS1
36-MONTH PFS IN POD24 PATIENTS
%
36-MONTH PFS in patients without POD24
%
OS1
36-MONTH PFS IN POD24 PATIENTS
%
36-MONTH PFS IN PATIENTS WITHOUT POD24
%
| CRR2 | |
|---|---|
| With POD24 | % |
| Without POD24 | % |
63% of patients in ELARA were POD241
36-month PFS and OS rates were consistent for patients with or without POD241
Outcomes with tisa-cel by age
Efficacy
CR1
ORR1
74% of patients in ELARA were under 65 years1
Median age: 57 (29−73)2
Tisa-cel induced consistently high response rates in patients aged <65 and ≥65 years1
N=97 patients infused with tisa-cel. N=94 in efficacy analysis set.
Median follow-up: 41 months
Outcomes with tisa-cel in patients with or without bulky disease
Efficacy
CR1
ORR1
64% of patients in ELARA had bulky disease2
Tisa-cel induced consistently high response rates in patients with or without bulky disease1
N=97 patients infused with tisa-cel. N=94 in efficacy analysis set.
Median follow-up: 41 months
Outcomes with tisa-cel in patients with or without high FLIPI
Efficacy
CR1
ORR1
60% of patients in ELARA had a high FLIPI score (≥3)2
Tisa-cel induced consistently high response rates in patients with or without high FLIPI scores1
N=97 patients infused with tisa-cel. N=94 in efficacy analysis set.
Median follow-up: 41 months
Outcomes with tisa-cel in patients by prior therapy
Efficacy
CR1
ORR1
Patients in ELARA had a median of 4 prior therapies2
Tisa-cel induced consistently high response rates in patients, irrespective of prior therapies1
N=97 patients infused with tisa-cel. N=94 in efficacy analysis set.
Median follow-up: 41 months
Outcomes with tisa-cel in patients who were double refractory
Efficacy
CR1
ORR1
68% of patients in ELARA were double refractory
to anti-CD20 mAb + alkylating agent2
Tisa-cel induced consistently high response rates even in patients who were double refractory1
N=97 patients infused with tisa-cel. N=94 in efficacy analysis set.
Median follow-up: 41 months
Outcomes with tisa-cel in patients with or without prior Auto SCT
Efficacy
CR1
ORR1
36% of patients in ELARA had previously
undergone autologous stem cell transplantation2
Tisa-cel induced consistently high response rates, even in patients who have relapsed post Auto SCT1
N=97 patients infused with tisa-cel. N=94 in efficacy analysis set.
Median follow-up: 41 months
Patient
summary
Your patient summary will be shown here as you save you patient selections
This is where your patient summary will be shown. If you would like more tailored data, create a patient profile
Start a patient profileFL PATIENT
Patient profile
- Incomplete
Treatment history
- Incomplete